Raffaele De Lucia

Dr. Raffaele De Lucia


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
LSLuca Segreti
Luca Segreti
ASAntonio De Simone
Antonio De Simone
VSVincenzo Schillaci
Vincenzo Schillaci
MBMaria Grazia Bongiorni
Maria Grazia Bongiorni
GPGemma Pelargonio
Gemma Pelargonio
FSFrancesco Solimene
Francesco Solimene

28 October 2025 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
AMAnnette Maznyczka
Annette Maznyczka
RNRutger-Jan Nuis
Rutger-Jan Nuis
ISIsaac Shiri
Isaac Shiri
JTJulien Ternacle
Julien Ternacle
PGPhilippe Garot
Philippe Garot
OBOle De Backer
Ole De Backer

23 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Panteleimon PantelidisPanteleimon Pantelidis
Panteleimon Pantelidis
Polychronis DilaverisPolychronis Dilaveris
Polychronis Dilaveris
SRSamuel Ruipérez-Campillo
Samuel Ruipérez-Campillo
AGATHINA GOLIOPOULOU
ATHINA GOLIOPOULOU
AGAlexios Giannakodimos
Alexios Giannakodimos
GSGerasimos Siasos
Gerasimos Siasos
Artificial intelligence (AI) is transforming cardiovascular medicine by enabling the analysis of high-dimensional biomedical data with unprecedented precision. Initially employed to automate human tasks such as electrocardiogram (ECG) interpretation and imaging segmentation, AI’s true potential lies in uncovering hidden disease data patterns, predicting long-term cardiovascular risk, and personalizing treatments. Unlike human cognition, which excels in certain tasks but is limited by memory and processing constraints, AI integrates multimodal data sources—including ECG, echocardiography, cardiac magnetic resonance (CMR) imaging, genomics, and wearable sensor data—to generate novel clinical insights. AI models have demonstrated remarkable success in early dis-ease detection, such as predicting heart failure from standard ECGs before symptom on-set, distinguishing genetic cardiomyopathies, and forecasting arrhythmic events. However, several challenges persist, including AI’s lack of contextual understanding in most of these tasks, its “black-box” nature, and biases in training datasets that may contribute to disparities in healthcare delivery. Ethical considerations and regulatory frameworks are evolving, with governing bodies establishing guidelines for AI-driven medical applications. To fully harness the potential of AI, interdisciplinary collaboration among clinicians, data scientists, and engineers is essential, alongside open science initiatives to promote data accessibility and reproducibility. Future AI models must go beyond task automation, focusing instead on augmenting human expertise to enable proactive, precision-driven cardiovascular care. By embracing AI’s computational strengths while addressing its limitations, cardiology is poised to enter an era of transformative innovation beyond traditional diagnostic and therapeutic paradigms.

17 February 2020 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
RLRaffaele De Lucia
Raffaele De Lucia
GZG. Zucchelli
G. Zucchelli
VBV. Barletta
V. Barletta
ACA. Di Cori
A. Di Cori
MSM. Giannotti Santoro
M. Giannotti Santoro
MBM. G. Bongiorni
M. G. Bongiorni

20 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Andrea Di CoriAndrea Di Cori
Andrea Di Cori
MPMatteo Parollo
Matteo Parollo
FFFederico Fiorentini
Federico Fiorentini
SVSalvatore Della Volpe
Salvatore Della Volpe
LMLorenzo Mazzocchetti
Lorenzo Mazzocchetti
GZGiulio Zucchelli
Giulio Zucchelli
Introduction: Transcatheter atrial fibrillation (AF) ablation is still carried out with continuous invasive radial arterial blood pressure (IBP) monitoring in many centers. Continuous noninvasive blood pressure (CNBP) measurement using the volume-clamp method is a noninvasive alternative method used in ICU. No data on CNBP reliability are available in the electrophysiology lab during AF ablation, where rhythm variations are common. Background: The objective of the present study was to compare continuous noninvasive arterial pressure measured with the ClearSight device (Edwards Lifesciences, Irvine, CA, USA) with invasive radial artery pressure used as the reference method during AF ablation. Methods: We prospectively enrolled 55 consecutive patients (age 62 ± 11 years, 80% male) undergoing transcatheter AF ablation (62% paroxysmal, 38% persistent) at our center. Standard of care IBP monitoring via a radial cannula and a contralateral noninvasive finger volume-clamp CNBP measurement device were positioned simultaneously in all patients for the entire procedure. Bland-Altman analysis was used to analyze the agreement between the two techniques. Results: A total of 1219 paired measurements for systolic, diastolic, and mean arterial pressure were obtained in 55 subjects, with a mean (SD) of 22 (9) measurements per patient. The mean bias (SD) was −12.97 (13.89) mmHg for systolic pressure (level of agreement −14.24–40.20; correlation coefficient 0.84), −1.85 (8.52) mmHg for diastolic pressure (level of agreement −18.54–14.84; correlation coefficient 0.77) and 2.31 (8.75) mmHg for mean pressure (level of agreement −14.84–19.46; correlation coefficient 0.85). Conclusion: In patients undergoing AF ablation, CNBP monitoring with the ClearSight device showed acceptable agreement with IBP monitoring. Larger studies are needed to confirm the potential clinical implications of continuous noninvasive BP monitoring during AF ablation.

24 January 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
RLRaffaele De Lucia
Raffaele De Lucia
CGCristina Giannini
Cristina Giannini
MPMatteo Parollo
Matteo Parollo
VBValentina Barletta
Valentina Barletta
GCGiulia Costa
Giulia Costa
APAnna Sonia Petronio
Anna Sonia Petronio
Permanent pacemaker implantation (PPM-I) remains nowadays the most important drawback of transcatheter aortic valve replacement (TAVR) procedure and the optimal strategy of delayed conduction disturbances (CDs) in these patients is unclear. The study aimed to validate an ambulatory electrocardiogram (ECG) monitoring through a 30 s spot ambulatory digital mobile ECG (AeECG), by using KardiaMobile-6L device in a 30-day period after TAVR procedure. Between March 2021 and February 2022, we consecutively enrolled all patients undergoing TAVR procedure, except pacemaker (PM) carriers. At discharge, all patients were provided of a KardiaMobile-6L device and a spot digital ECG (eECG) recording 1 month schedule. Clinical and follow-up data were collected, and eECG schedule compliance and recording quality were explored. Among 151 patients without pre-existing PM, 23 were excluded for pre-discharge PPM-I, 18 failed the KardiaMobile-6L training phase, and 10 refused the device. Delayed CDs with a Class I/IIa indication for PPM-I occurred in eight patients (median 6 days). Delayed PPM-I vs. non-delayed PPM-I patients were more likely to have longer PR and QRS intervals at discharge. PR interval at discharge was the only independent predictor for delayed PPM-I at multivariate analysis. The overall eECG schedule compliance was 96.5%. None clinical adverse events CDs related were documented using this new AeECG monitoring modality. A strategy of 30 s spot AeECG is safe and efficacious in delayed CDs monitoring after TAVR procedure with a very high eECG schedule level of compliance. (A) Flow chart programme for patient access to the device training phase and its rules. (B) eECG 1 month schedule. (C ) Histogram illustrating the number of cases and associated time to development of delayed CDs requiring PPM-I. CD, conduction disturbance; eECG, digital electrocardiogram; PPM-I, permanent pacemaker implantation.